Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates
with symptomatic congenital cytomegalovirus infection with central nervous system disease.
Phase:
Phase 3
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)